Gland Pharma GLAND
B2B sterile injectables developer and contract manufacturer (vials, bags, prefilled syringes) for global generic and innovator companies; owns Cenexi in Europe
Mapped in 1 theme: Pharmaceuticals.
Where Gland Pharma sits in the supply chain
Gland Pharma appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Sterile injectables & fill-finish
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 5,665 | 5,616 | 6,431 |
| Net profit | 772 | 699 | 1,027 |
Latest-year revenue ₹6,431 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Pure-play injectables with a long USFDA-compliant record in Hyderabad
- Recovery under way: FY26 profit ₹1,027 Cr (+47%); stock recovered strongly from its 52-week low in the year to Oct 2026
- Building GLP-1 / peptide fill-finish and biologics CDMO capacity
Risks
- Controlled by China's Shanghai Fosun Pharma - a perception risk with US customers in a BIOSECURE world
- Cenexi (France) turnaround still dilutes margins
- Customer and product concentration
Common questions
What does Gland Pharma do?
B2B sterile injectables developer and contract manufacturer (vials, bags, prefilled syringes) for global generic and innovator companies; owns Cenexi in Europe.
Where does Gland Pharma sit in the supply chain?
Gland Pharma (NSE: GLAND) is mapped in 1 supply-chain layer: Sterile injectables & fill-finish (Pharmaceuticals).
Who are Gland Pharma's peers?
In the Sterile injectables & fill-finish layer of Pharmaceuticals: Aurobindo Pharma, Caplin Point Laboratories, Piramal Pharma and Alembic Pharmaceuticals.
What is Gland Pharma's market cap and valuation?
As of 30 Oct 2026: market cap ₹51,080 Cr, P/E 44.6x, ROCE 15.1%, ROE 10.7%, dividend yield 0.65%.